<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Antimalarial drugs in the treatment of rheumatic disease</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Antimalarial drugs in the treatment of rheumatic disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Antimalarial drugs in the treatment of rheumatic disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel J Wallace, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel E Furst, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer E Thorne, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Siobhan M Case, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 24, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>A variety of antimalarial medications have been shown to be effective for systemic rheumatic diseases since <a class="drug drug_general" data-topicid="9847" href="/z/d/drug information/9847.html" rel="external">quinine</a> was first used to treat systemic lupus erythematosus (SLE) more than 100 years ago. Three of these drugs are now primarily used due to their safety profile.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">Chloroquine</a> and <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a> (HCQ) are 4-aminoquinoline derivatives. They are structurally similar, differing only by replacement of an ethyl group in chloroquine with a hydroxyethyl group in HCQ. HCQ comprises 95 percent of all rheumatic disease antimalarial prescriptions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Quinacrine (mepacrine) incorporates the <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a> structure but is a 9-aminoacridine compound. It causes a yellowish skin color with long-term treatment and is no longer commercially available in most settings.</p><p></p><p class="headingAnchor" id="H2"><span class="h1">PHARMACOLOGY</span></p><p class="headingAnchor" id="H654269921"><span class="h2">Pharmacokinetics</span><span class="headingEndMark"> — </span>There are several problems in analysis of the pharmacokinetics of antimalarials:</p><p class="bulletIndent1"><span class="glyph">●</span>Variation from individual to individual is wide.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Disease states may affect metabolism (eg, increased protein binding in patients with active rheumatoid arthritis [RA]).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Metabolic differences between agents can be seen even with compounds as structurally similar as <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a> and <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a> (HCQ).</p><p></p><p>Despite these difficulties, it appears that absorption of antimalarial drugs averages around 70 percent and is not affected by diarrhea. The mean absorption half-life is four hours with a lag time of slightly more than 30 minutes [<a href="#rid1">1</a>]. The terminal half-life for <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a> and HCQ is one to two months [<a href="#rid2">2</a>].</p><p>The (S) enantiomer of HCQ (50 percent of the commercial product) has greater bioavailability but a shorter half-life than the (R) enantiomer and holds promise for formulation as a more potent product with less eye toxicity potential [<a href="#rid3">3,4</a>].</p><p>Tissue distribution is wide with accumulation in muscle, liver, spleen, kidney, lung, blood elements, adrenal and pituitary glands, and melanin-containing tissue [<a href="#rid5">5</a>]. <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">Chloroquine</a> binds to corneal tissue more avidly than HCQ [<a href="#rid6">6</a>].</p><p>Steady state antimalarial blood concentrations vary greatly; 94 percent equilibrium is achieved by quinacrine in four weeks compared with 96 percent by HCQ in six months. The major metabolite of <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a>, desethylchloroquine, can reach blood levels nearly one-half those of the parent compound [<a href="#rid7">7</a>].</p><p>Because of the considerable time required to reach equilibrium, higher (loading) doses have been assessed in patients with RA. Although higher daily doses (up to 1200 mg per day for six weeks) are associated with higher blood concentrations of HCQ and its metabolites and with more rapid onset of beneficial clinical effects, such high-dose regimens are also associated with more frequent adverse gastrointestinal side effects [<a href="#rid8">8,9</a>].</p><p class="headingAnchor" id="H3"><span class="h2">Renal clearance</span><span class="headingEndMark"> — </span>Excretion of these drugs is principally by direct renal clearance of the parent compound and hepatic metabolites [<a href="#rid2">2,10</a>]. Thus, the drug dose should be reduced in patients with renal insufficiency [<a href="#rid2">2</a>]. We typically reduce the dose of HCQ to 200 mg daily in patients with end-stage kidney disease. Both <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a> and HCQ can cause a 10 percent decrease in creatinine clearance by competitively inhibiting creatinine secretion; this does not represent a true change in renal function. Antimalarials have been found in the urine five years after medication was stopped [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H983205348"><span class="h2">Drug interactions</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">Chloroquine</a> phosphate (CP) is metabolized by cytochromes 2D6 and 3A4 and can prolong the QTc interval on the electrocardiogram. In contrast, HCQ is subject to fewer significant pharmacokinetic drug interactions, and most evidence suggests that it has a lower risk of prolonging the QTc interval. Before initiating or altering therapy, specific interactions with other medications should be checked by use of a <a class="external" href="/drug-interactions">drug interactions program</a>, such as the <a class="external" href="/drug-interactions">drug interactions program</a> provided by UpToDate. Examples are provided for illustration; this is not an exhaustive list:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antacids</strong> – The oral bioavailability of CP is reduced when taken with antacids (eg, <a class="drug drug_general" data-topicid="9185" href="/z/d/drug information/9185.html" rel="external">calcium carbonate</a>); separate administration by four or more hours [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Additive QTc prolongation</strong> – CP prolongs the QTc interval, which can rarely lead to a life-threatening arrhythmia, torsade de points; HCQ appears to be relatively lower risk [<a href="#rid13">13-17</a>]. Risk is additive when either is used with other drugs that prolong the QTc interval (eg, other antimalarials [artemether, halofantrine, <a class="drug drug_general" data-topicid="9602" href="/z/d/drug information/9602.html" rel="external">mefloquine</a>], intravenous [IV] <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">haloperidol</a>); use with drugs that prolong QTc interval  (<a class="graphic graphic_table graphicRef57431" href="/z/d/graphic/57431.html" rel="external">table 1</a>) and also increase <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a> levels via CYP interactions (eg, <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">clarithromycin</a>, <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a>) are of greater concern, and such combinations should generally be avoided. (See  <a class="medical medical_review" href="/z/d/html/1043.html" rel="external">"Acquired long QT syndrome: Definitions, pathophysiology, and causes"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CYP interactions</strong> – CP, but not HCQ, is dependent on CYP2D6 and CYP3A4 hepatic metabolism for clearance; CP levels may be altered when taken with drugs that strongly interact with CYP2D6 or CYP3A4 metabolism; lists of such drugs are provided in the tables  (<a class="graphic graphic_table graphicRef116164" href="/z/d/graphic/116164.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef76992" href="/z/d/graphic/76992.html" rel="external">table 3</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypoglycemics</strong> – HCQ and CP can increase risk of hypoglycemia with antidiabetic agents (eg, sulfonylureas, insulins, others), although this is rarely observed in clinical practice [<a href="#rid12">12,18</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other</strong> – HCQ and CP can increase <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> and <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> levels [<a href="#rid19">19-21</a>].</p><p></p><p class="headingAnchor" id="H6"><span class="h2">Mechanism of action</span><span class="headingEndMark"> — </span>Antimalarials have a wide variety of actions, a number of which may be responsible for their immunomodulatory effects [<a href="#rid22">22,23</a>]. The most important mechanisms of action that affect the inflammatory diseases include their effects on the innate immune system and their lysosomotropic actions. Potential mechanisms of action include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>One of the most important actions deals with its actions related to toll-like receptors (TLRs). Cytosine phosphate diester-guanine (CpG) deoxyribonucleic acid (DNA) stimulates cells through TLR-9, which is found in lysosomes. Chloroquines may block costimulation of the B cell antigen receptor and TLR-9 pathways and, thus, may act as an antiinflammatory agent [<a href="#rid24">24,25</a>]. Furthermore, antimalarials can inhibit activation of intracellular TLR-3 and TLR-7 [<a href="#rid26">26</a>]. Finally, HCQ appears to exert an inhibitor effect on TLR signaling [<a href="#rid27">27</a>]. Nucleic acid-sensing TLRs are located intracellularly and are activated by foreign nucleic acids that are presented to them by intermediate molecules, such as Fc-gamma receptors. TLRs are processed by endosomes before becoming active; thus, antimalarial inhibition of endosomal activation inhibits TLR activation. In addition, the binding of nucleic acids to TLR through nucleic acid-binding epitopes is also mechanically inhibited by antimalarial binding that masks these epitopes [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another important mechanism appears to be interference with normal physiologic function of subcellular compartments that depend upon an acidic milieu. This effect is termed a "lysosomotropic action" because it was first demonstrated in lysosomes. Antimalarials are weak bases that enter not just lysosomes but all acidic compartments in which they are protonated, that raise the pH, and that interfere with functions dependent upon an acidic pH [<a href="#rid29">29</a>]. Antimalarials antagonize immune stimulation by CpG DNA (a ligand for TLR-9), and <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a> inhibits immune stimulation by small nuclear ribonucleic acid (RNA; a ligand for TLR-7) and subsequent production of interferon alpha. TLRs require an acidic pH; thus, an increase in lysosomal pH caused by antimalarials may prevent functional transformation of intracellular TLRs and may inhibit their activation.</p><p></p><p class="bulletIndent1">This mode of action has many secondary effects. It interferes with receptor recycling, intracellular processing, and the secretion of proteins, which leads to a decreased production of cytokines and other inflammatory mediators [<a href="#rid11">11,30-32</a>]. Immune effects include decreased lymphocyte proliferation [<a href="#rid11">11</a>], interference with natural killer cell activity [<a href="#rid11">11</a>], and, possibly, alteration of autoantibody production [<a href="#rid33">33</a>]. In addition, antimalarials may influence the binding of autoantigenic peptides to major histocompatibility complex (MHC) class II molecules, thereby interfering with antigen processing and ultimately with the immune response to autoantigens [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>It has also been suggested that decreased secretion of monocyte-derived proinflammatory cytokines may be due to nonlysosomotropic effects of antimalarials. These include a decrease in secretion of tumor necrosis factor (TNF)-alpha by stimulated human peripheral blood-derived mononuclear cells in response to <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a>, which was associated with decreased amounts of TNF-messenger RNA [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other actions may play a role in the antirheumatic activity of antimalarials. Antiinflammatory effects may include inhibiting phospholipases, antagonizing prostaglandin, stabilizing lysosomal membranes, inhibiting T- and B-cell receptor calcium signaling, decreasing fibronectin release by macrophages, blocking superoxide release, and decreasing metalloproteinase production by synoviocytes [<a href="#rid34">34,36-38</a>]. These drugs also block ultraviolet light absorption, an effect that may protect against lupus skin lesions [<a href="#rid39">39</a>].</p><p></p><p class="headingAnchor" id="H2134596835"><span class="h1">ADMINISTRATION, DOSING, AND MONITORING</span></p><p class="headingAnchor" id="H3275117093"><span class="h2">Preparations</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">Hydroxychloroquine</a> (HCQ) sulfate is available as a 200 mg tablet. <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">Chloroquine</a> phosphate (CP) is available in 250 mg and 500 mg tablets. Doses in this topic are expressed as hydroxychloroquine sulfate <strong>salt</strong> and chloroquine phosphate <strong>salt</strong>, following labeling conventions of North America [<a href="#rid12">12,18</a>]. In some countries outside of North America, chloroquine (and less frequently HCQ) strengths are expressed as base or as another salt form (eg, chloroquine sulfate or hydrochloride), and different tablet strengths may be available.</p><p>To avoid a dosing error, locally available product information should be consulted to confirm strength and equivalence for the specific preparation. The following equivalences may be useful:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">Hydroxychloroquine</a> sulfate 200 mg salt contains 155 mg of hydroxychloroquine base [<a href="#rid18">18</a>]</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">Chloroquine</a> phosphate 500 mg salt contains 300 mg chloroquine base [<a href="#rid12">12</a>]</p><p></p><p>Some generic preparations of both HCQ and CP come as scored tablets and can be split or cut in one-half. Additional information is available in the drug monographs included within UpToDate for <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a> and <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a>. Quinacrine (mepacrine) is no longer commercially available in most settings [<a href="#rid40">40,41</a>].</p><p class="headingAnchor" id="H2454200884"><span class="h2">Dose adjustment for weight</span><span class="headingEndMark"> — </span>For patients who require HCQ for the chronic treatment of systemic rheumatic diseases or related conditions, we suggest a maximum daily dose of 5 mg/kg/day of actual body weight. Dosing may be once daily, if tolerated.</p><p>Patients who weigh more than 80 kg can receive the standard daily dose of HCQ of 400 mg daily. Tablets may be split or variable dosing (eg, alternating or skipping doses on certain days) may be required to meet the recommended dose limits. Similar demographic data for <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a> are lacking, but dose comparisons have led to a suggested maximum daily dose of 2.3 mg/kg. These dosing recommendations are in agreement with the revised screening guidelines from the American Academy of Ophthalmology (AAO) and other professional societies [<a href="#rid42">42,43</a>]. Occasionally, there are instances in which short-term use (never exceeding two to three months) of higher doses may be required for better disease control. As an example, a higher dose of HCQ of 7 mg/kg daily (up to 600 mg daily) for several weeks may be helpful for treatment of an acute flare of discoid lesions.</p><p>The maximum dose limits for HCQ and <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a> described above are based on data from a large healthcare organization database in which 2361 HCQ users were identified, all of whom had undergone more sensitive screening methods (ie, central visual field examination or spectral domain optical coherence imaging) for retinopathy [<a href="#rid44">44</a>]. This case-control study found an overall prevalence of HCQ retinopathy of 7.5 percent, which was much higher than the risk of less than 2 percent that had been previously reported, but may be related to more sensitive measurement techniques [<a href="#rid45">45-48</a>]. The risk of retinopathy increased with higher doses of HCQ and longer duration of therapy. In patients treated with 4 to 5 mg/kg, the prevalence of retinal toxicity was less than 2 percent during the first 10 years of therapy, but the risk increased to nearly 20 percent after 20 years of use. The annual risk after an examination showing no evidence of toxicity in patients using no more than 5 mg/kg was less than 1 percent during the first 10 years of use, but rose to almost 4 percent per year after 20 years. The risk of retinopathy was also increased in patients with kidney disease (odds ratio [OR] 2.08, 95% CI 1.44-3.01) and those concurrently taking <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a> (OR 4.59, 95% CI 2.05-10.27), which is also retinotoxic. In addition, this study found that dose calculation by real body weight was a better predictor of risk than ideal body weight. It was this study that prompted a renewed concern regarding the appropriate dosing of HCQ, which had been previously recommended by major guideline organizations as being 6.5 mg/kg of ideal body weight (up to a maximum of 400 mg daily) [<a href="#rid49">49</a>].</p><p>Another study of 3325 HCQ users who underwent routine retinal scans found that the overall cumulative incidence of moderate to severe retinopathy at 15 years was 1.1 percent among patients taking 5 mg/kg/day but increased to 5.9 percent among patients taking more than 6 mg/kg/day [<a href="#rid50">50</a>]. The risk of retinopathy was higher among patients who were at least 55 years old or had at least chronic kidney disease (CKD) stage 3 at the time of HCQ initiation.</p><p class="headingAnchor" id="H2894446137"><span class="h2">Monitoring for toxicity</span><span class="headingEndMark"> — </span>With the exception of routine eye examinations for retinopathy, monitoring for other adverse effects is typically clinical. Otherwise, the relative safety of antimalarials is reflected by the fact that no regular laboratory tests are needed to monitor for other toxicities [<a href="#rid51">51</a>].</p><p class="headingAnchor" id="H2556033887"><span class="h3">Routine eye examinations</span><span class="headingEndMark"> — </span>Monitoring patients with routine eye exams is necessary to avoid permanent vision loss, although the incidence of retinal toxicity is reduced through the use of lower doses of medication (see <a class="local">'Dose adjustment for weight'</a> above). The purpose of screening is to detect retinal toxicity, if it develops, before the vision is affected. The primary screening tests are automated visual fields and spectral domain optical coherence tomography (SD-OCT). Early OCT changes are almost always asymptomatic and may remain so if HCQ is discontinued. Asian and Asian American patients tend to show early damage outside the central macula and can develop serious toxicity before it would be recognized by tests that focus only on the parafovea; thus, imaging studies in this population should examine beyond the central macula [<a href="#rid42">42,52</a>]. </p><p>We advise assessment of ocular health within a year of starting long-term antimalarial drug therapy. The baseline examination should include a fundus examination of the macula to rule out any underlying disease that may interfere with the interpretation of screening tests. The frequency of subsequent screening during the first five years of treatment may be individualized based upon assessment of risk. We prefer annual screening exams for all patients, but the AAO has suggested that for patients with a normal baseline exam who do not have major risk factors for toxic retinopathy, follow-up examinations may be deferred until there have been five years of exposure [<a href="#rid42">42</a>]. Major risk factors for toxic retinopathy include a daily dose of HCQ greater than 5 mg/kg real body weight or a daily dose of <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a> greater than 2.3 mg/kg real body weight, antimalarial use for greater than five years, the presence of renal disease, concomitant <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a> use, and/or the presence of macular disease. Patients should be alert for any change in visual acuity and should seek medical attention promptly if any visual loss is noted. Antimalarials should be discontinued immediately if there is any suspicion of retinopathy. Additional details regarding the potential adverse ocular effects associated with antimalarials are discussed further below. (See <a class="local">'Ocular effects'</a> below.)</p><p>Indirect evidence from limited observational data suggest that early screening for HCQ toxicity can reduce the risk of losing visual acuity. A study of 22 patients with different degrees of HCQ retinopathy reported a range of changes during follow-up after cessation of HCQ whose magnitude correlated with retinopathy severity at the time of cessation [<a href="#rid53">53</a>]. The eyes with the least severe retinopathy at the time of drug cessation demonstrated a low likelihood of progression and there was even some functional and structural improvement in some cases. Eyes with more severe retinopathy, however, demonstrated progressive deterioration of retinal structures and a decline in function even years after cessation of the drug. Another small study with 11 patients with different degrees of HCQ retinopathy also detected a similar pattern in which less severe retinopathy demonstrated little progression during the follow-up period, in contrast with more severe retinopathy that continued to progress during the three-year follow-up period [<a href="#rid54">54</a>].</p><p>Our approach to monitoring for retinal toxicity is generally consistent with that of major professional societies [<a href="#rid43">43</a>].</p><p class="headingAnchor" id="H2439785500"><span class="h2">Limited role of blood level testing</span><span class="headingEndMark"> — </span>There are available laboratory tests to check levels of HCQ and its metabolites, but the role of routine testing in clinical care is somewhat uncertain.</p><p class="headingAnchor" id="H629828812"><span class="h3">Adherence monitoring</span><span class="headingEndMark"> — </span>There has been an increased interest in blood level testing to identify patients who are nonadherent. An undetectable serum HCQ level indicates that the patient is not taking the drug. Nonadherence is a known challenge following patients with systemic rheumatic diseases. Adherence in systemic lupus erythematosus (SLE) has been estimated to be as low as 20 percent in some studies [<a href="#rid55">55,56</a>]. The impact of blood HCQ concentrations on efficacy was evaluated in a prospective six-month study of 143 patients who received 400 mg per day [<a href="#rid57">57</a>]. Patients with active disease were found to have lower blood levels. These results were supported by additional reports in which low blood concentrations of HCQ were markers for and predictors of disease flares in patients with SLE [<a href="#rid57">57-61</a>]. In one study, in which adherence was defined as the presence of a therapeutic drug level (at least 500 ng/mL), the measurement of the HCQ blood level, together with counseling regarding dosing and repeated testing, resulted in an increase in adherence from 56 percent (at baseline) to 80 percent (after three or more visits at which levels were assessed) [<a href="#rid59">59</a>].</p><p class="headingAnchor" id="H3930829372"><span class="h3">Dose adjustment</span><span class="headingEndMark"> — </span>In the future, monitoring of whole blood HCQ levels may be used to adjust HCQ dosing. The same dose of HCQ may lead to different serum HCQ levels due to variations in how the drug is metabolized. One study of 537 patients with SLE indicated that both the mean and maximum whole blood HCQ levels correlate with the risk of developing HCQ retinopathy [<a href="#rid62">62</a>]. In this cohort, 6.7 percent of patients with a HCQ level greater than 1753 ng/mL developed HCQ retinopathy. However, only 1.2 percent of patients with a HCQ level less than 1182 ng/mL developed HCQ retinopathy. A meta-analysis representing 1233 patients indicated that a HCQ level greater than 750 ng/mL was associated with a 58 percent lower risk of active disease [<a href="#rid63">63</a>]. Taken together, these studies imply HCQ dosing may be individualized to minimize the risk of HCQ toxicity while retaining the therapeutic benefits of this drug.</p><p class="headingAnchor" id="H1394848383"><span class="h1">NONINFECTIOUS INDICATIONS FOR ANTIMALARIALS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of specific systemic rheumatic diseases</strong> – The immunoregulatory and antiinflammatory properties of antimalarials have been effective in the treatment of various systemic rheumatic disease. As an example, antimalarials are used to treat certain non-life-threatening manifestations of systemic lupus erythematosus (SLE) and patients with mild or moderately active rheumatoid arthritis (RA). Information regarding the effectiveness and safety of these agents in the treatment of other rheumatic disorders and of musculoskeletal and cutaneous manifestations is discussed in the management sections that deal with treatment of the specific diseases, several of which are listed here:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>SLE (see  <a class="medical medical_review" href="/z/d/html/4675.html" rel="external">"Overview of the management and prognosis of systemic lupus erythematosus in adults", section on 'Approach to drug therapy'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>RA (see  <a class="medical medical_review" href="/z/d/html/7477.html" rel="external">"Alternatives to methotrexate for the initial treatment of rheumatoid arthritis in adults", section on 'Hydroxychloroquine'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Sjögren's disease (see  <a class="medical medical_review" href="/z/d/html/14923.html" rel="external">"Treatment of dry mouth and other non-ocular sicca symptoms in Sjögren’s disease", section on 'Systemic antiinflammatory and immunosuppressive therapy'</a> and  <a class="medical medical_review" href="/z/d/html/113735.html" rel="external">"Treatment of Sjögren's disease: Constitutional and non-sicca organ-based manifestations", section on 'Conventional immunosuppressive drugs and nonbiologic DMARDs'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Antiphospholipid syndrome (see  <a class="medical medical_review" href="/z/d/html/4682.html" rel="external">"Management of antiphospholipid syndrome", section on 'Other treatment considerations'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cutaneous dermatomyositis (see  <a class="medical medical_review" href="/z/d/html/13771.html" rel="external">"Cutaneous dermatomyositis in adults: Overview and initial management", section on 'Hydroxychloroquine'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Palindromic rheumatism (see  <a class="medical medical_review" href="/z/d/html/7502.html" rel="external">"Clinical manifestations of rheumatoid arthritis", section on 'Palindromic rheumatism'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other beneficial properties</strong> – Antimalarials have also been found to have favorable metabolic and antithrombotic effects [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Metabolic effects</strong> – Limited data have shown that antimalarial agents favorably affect serum lipid concentrations as well as blood glucose. As an example, when fasting lipid profiles were assessed in 123 patients with SLE (nearly one-half of whom were taking antimalarials), the mean serum concentrations of total, low density, and very low density cholesterol were significantly lower in those taking antimalarials (12, 16, and 22 percent less than patients not taking these agents, respectively) [<a href="#rid64">64</a>]. High density cholesterol levels are unaffected by antimalarial use [<a href="#rid64">64,65</a>].</p><p></p><p class="bulletIndent2">A small randomized trial indicated that <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a> (HCQ) improves glycemic control in patients with type 2 diabetes mellitus who are refractory to treatment with sulfonylureas [<a href="#rid66">66</a>]. These data were supported by a large observational study from the Arthritis, Rheumatism, and Aging Medical Information System (ARAMIS) database that reported a reduced risk of diabetes mellitus among patients who received HCQ for RA compared with those who did not [<a href="#rid67">67</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Antithrombotic effects</strong> – HCQ is also a mild anticoagulant. It inhibits platelet aggregation and adhesion without altering the bleeding time, and its use is not associated with increased bleeding [<a href="#rid29">29</a>]. It may decrease the risk of thrombotic events in patients with SLE [<a href="#rid68">68-70</a>], which may be mediated through protecting the annexin A5 anticoagulant shield [<a href="#rid71">71</a>]. It also has a weak inhibitory effect on acetylcholinesterase; a resulting increase in synaptic transmission at neuroglandular sites may contribute to stimulation of salivary flow in Sjögren's disease [<a href="#rid72">72</a>].</p><p></p><p class="headingAnchor" id="H7"><span class="h1">ADVERSE EFFECTS</span><span class="headingEndMark"> — </span>Antimalarials are among the safest medications used for the treatment of systemic rheumatic diseases [<a href="#rid73">73</a>]. Serious side effects are extremely rare. The most common adverse reactions are related to the gastrointestinal tract, skin, and central nervous system (CNS). The fear of vision-threatening toxic retinopathy remains a major concern, although this can be avoided when using the appropriate doses along with routine ocular monitoring.</p><p class="headingAnchor" id="H8"><span class="h2">Gastrointestinal involvement</span><span class="headingEndMark"> — </span>Gastrointestinal upset is the most common side effect necessitating discontinuation of antimalarials [<a href="#rid74">74</a>]. It is more common with <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a> than with <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a> (HCQ), even at doses of relatively equal efficacy (eg, 250 mg and 400 mg, respectively) [<a href="#rid75">75</a>]. Nausea is most common; it may be so severe that the patient does not wish to eat. Vomiting and diarrhea may also occur.</p><p>The gastrointestinal side effects are, in part, related to muscular effects that cause abdominal cramps. The antimalarials do not cause ulcer formation or life-threatening gastrointestinal complications. It may be possible to lessen these problems by taking the medication at bedtime. Alternatively, decreasing the dose to one half-pill daily or every other day, and then gradually increasing the dose every one to two weeks as tolerated, may result in improved patient tolerance. Some clinicians routinely start at one pill of HCQ daily (200 mg) and raise the dose after a week or two if it is well tolerated, as a way to minimize gastrointestinal side effects. Hepatotoxicity due to antimalarial agents is rare [<a href="#rid76">76</a>].</p><p class="headingAnchor" id="H9"><span class="h2">Skin changes</span><span class="headingEndMark"> — </span>A dermatologic reaction occurs in approximately 10 percent of patients treated with <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a> or HCQ. The lesions may be of almost any type and are allergic in nature. They most frequently appear as pruritic maculopapular lesions. It may be feasible to reintroduce antimalarial therapy to patients with drug hypersensitivity reactions using a slow oral desensitization regimen [<a href="#rid77">77</a>].</p><p>Patients receiving long-term therapy with <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a> or HCQ may develop hyperpigmentation, usually involving the oral mucosa, shins, nails, and forearms [<a href="#rid78">78</a>]. They can also develop hyper- or hypopigmentation of the hair and oral mucosa. The development of pigmented lesions appears to be more frequent in patients with conditions associated with easy bruising (eg, use of anticoagulants or antiplatelet agents) and usually preceded by local ecchymotic changes [<a href="#rid78">78,79</a>]. As noted above, quinacrine causes a reversible yellowing of the skin in most patients. In addition, some patients develop black and blue marks on the palate [<a href="#rid80">80</a>].</p><p>There have been conflicting reports regarding the safety of HCQ among patients with psoriatic skin lesions. While some case reports have suggested that HCQ is associated with exacerbations of psoriatic skin lesions, subsequent reports have found HCQ to be well-tolerated in patients with psoriasis [<a href="#rid81">81</a>].</p><p class="headingAnchor" id="H10"><span class="h2">Central nervous system involvement</span><span class="headingEndMark"> — </span>CNS side effects are usually not severe. Headaches are most common, followed by lightheadedness [<a href="#rid75">75</a>]. Both of these effects may disappear spontaneously within several weeks, although a temporary daily dose reduction may be needed.</p><p>Other problems include tinnitus, insomnia, and increased nervousness. Rare complications include psychosis and convulsions [<a href="#rid11">11,82</a>].</p><p class="headingAnchor" id="H11"><span class="h2">Neuromuscular toxicity</span><span class="headingEndMark"> — </span>Antimalarial drugs used in the treatment of rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) have been reported to cause a toxic neuropathy, drug-induced skeletal myopathy, cardiomyopathy, and rarely, cardiac arrhythmias [<a href="#rid83">83-88</a>]. Myopathy is a rare complication of these drugs; one study estimated the incidence to be 1 in 100 patient-years, although this has not been confirmed by others [<a href="#rid89">89</a>]. Most of the case reports of myopathy have involved CP, but HCQ has also been implicated [<a href="#rid90">90</a>]. A more detailed discussion of the myopathy associated with antimalarials is presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/5166.html" rel="external">"Drug-induced myopathies", section on 'Chloroquine/hydroxychloroquine'</a>.)</p><p class="headingAnchor" id="H3183140975"><span class="h2">Cardiotoxicity</span><span class="headingEndMark"> — </span>Cardiac conduction abnormalities, cardiomyopathy resulting in heart failure, and sudden cardiac arrest have occurred rarely in patients receiving long-term oral therapy with <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a> phosphate (CP) and <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a> (HCQ) for rheumatic diseases [<a href="#rid91">91-93</a>]. Long-term use of CP or HCQ has been recognized as a potential cause of direct myocardial injury and/or worsening clinical status in patients with pre-existing heart disease [<a href="#rid93">93</a>]. Depending upon the severity of the underlying cardiac disease, we generally avoid or use these agents with caution in patients with underlying heart disease and monitor all patients on long-term therapy for signs and symptoms of cardiac compromise. The risk of cardiomyopathy associated with the use of antimalarials is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/5166.html" rel="external">"Drug-induced myopathies", section on 'Chloroquine/hydroxychloroquine'</a>.)</p><p>As discussed above, both CP and HCQ have been associated with QTc interval prolongation, torsades de pointes, and ventricular arrhythmias. The risk of QTc prolongation appears to be greater with CP compared with HCQ [<a href="#rid16">16,94,95</a>], particularly if CP is administered at high doses or in patients taking other QT-prolonging medications  (<a class="graphic graphic_table graphicRef57431" href="/z/d/graphic/57431.html" rel="external">table 1</a>) or drugs that may elevate CP levels. Fatal cases have been reported. Thus, CP and HCQ should be avoided in patients with congenital long QT syndrome, persistent corrected QT measurements &gt;500 milliseconds, bradycardia, a history of ventricular arrhythmias, uncorrected hypokalemia and/or hypomagnesemia, recent myocardial infarction, or uncompensated heart failure; for patients taking other drugs that prolong the QT interval or elevate CP levels, consideration should be given to discontinuing these other drugs, as well as the benefit of adding CP or HCQ versus the risk of toxicity, <strong>prior to initiating therapy</strong>. (See <a class="local">'Drug interactions'</a> above and  <a class="medical medical_review" href="/z/d/html/116011.html" rel="external">"Acquired long QT syndrome: Clinical manifestations, diagnosis, and management", section on 'Precautions for any patient starting QT-prolonging drugs'</a>.)</p><p class="headingAnchor" id="H12"><span class="h2">Ocular effects</span><span class="headingEndMark"> — </span>Serious ophthalmologic toxicity is relatively rare if the patient is periodically monitored but remains the most feared adverse effect of antimalarial drugs since it can result in loss of vision. The two main ocular toxicities of antimalarials relate to the cornea (always reversible) and retinopathy (irreversible).</p><p class="headingAnchor" id="H14"><span class="h3">Retinopathy</span><span class="headingEndMark"> — </span>As mentioned above, vision-threatening toxic retinopathy is the most important ophthalmologic complication of antimalarial therapy [<a href="#rid96">96</a>]. The exact mechanism in which HCQ and <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a> can lead to retinopathy is not entirely clear [<a href="#rid97">97</a>]. It had been hypothesized that antimalarials bind to melanin in the retinal pigment epithelium (RPE), an effect that may damage the overlying photoreceptors and may lead to permanent vision loss. It is still a matter of debate as to whether the primary effect of the antimalarials occurs at the level of the RPE or the photoreceptors.</p><p>Estimates of risk are higher than previously thought due to the availability of more sensitive screening methods. The risk of retinopathy also appears to increase with higher doses and a longer duration of therapy [<a href="#rid44">44,45</a>]. This is discussed in detail above. (See <a class="local">'Dose adjustment for weight'</a> above.)</p><p>The earliest retinal abnormalities are asymptomatic and can only be detected by ophthalmologic examination. These "premaculopathy" changes consist of macular edema, increased pigmentation, increased granularity, and loss of the foveal reflex. Subtle functional loss in the paracentral retina can occur before biomicroscopic changes in the RPE [<a href="#rid98">98-100</a>]. Detection of changes at this stage, using techniques such as spectral domain optical coherence tomography (SD-OCT) and multifocal electroretinography, is desirable since such changes are likely to stabilize without loss of visual acuity and, in some cases, retinopathy may be completely reversible upon discontinuation of the medication [<a href="#rid54">54,101</a>]. With the advanced electrophysiological screening methods, up to 7 percent of patients taking HCQ have retinal changes after five years of use [<a href="#rid44">44</a>]. These are rarely symptomatic but may require alterations in the dosing regimen and drug discontinuation.</p><p>More advanced macular disease, a true retinopathy, is characterized by a central patchy area of depigmentation of the macula surrounded by a concentric ring of pigmentation, a "bull's eye" lesion. Symptoms at this stage are generally not reversible and may include a dropout of letters from words when reading, photophobia, blurred distance vision, reduced night vision, visual field defects, and flashing lights [<a href="#rid36">36,102</a>]. Severe retinopathy, including RPE damage, has been shown on SD-OCT to progress for at least three years following drug discontinuation [<a href="#rid54">54</a>]; depigmentation and functional loss may continue for one year or more after the drug has been stopped [<a href="#rid49">49</a>].</p><p>In addition to the typical parafoveal (bulls-eye) changes, many patients with HCQ toxicity have a mixed pattern that also includes pericentral (arcade region) changes, and some patients only exhibit a pericentral pattern of damage, with changes limited to the periphery of the field examined by usual screening techniques [<a href="#rid103">103</a>]. A mixed pattern of damage or changes in the pericentral pattern alone are especially common among those of Asian ancestry [<a href="#rid52">52,103</a>].</p><p class="headingAnchor" id="H531611938"><span class="h3">Corneal deposits</span><span class="headingEndMark"> — </span>Deposits of the drug or metabolites on the cornea are related to high daily doses. This effect is more common with <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a>, although the incidence per daily dose is not known [<a href="#rid104">104</a>]. Corneal deposits are rare with HCQ at a dose of 400 mg/day. The deposits do not affect vision but can create transient halos or heightened light sensitivity, and they are reversible upon discontinuation of the medication.</p><p class="headingAnchor" id="H15"><span class="h2">Other</span><span class="headingEndMark"> — </span>Rare toxicities include agranulocytosis and aplastic anemia with <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a> and quinacrine; there has never been a report of this occurring with HCQ in doses less than 7 mg/kg/day. Fatal accidental overdose has occurred in children under age six who ingested one or two tablets of chloroquine; doses of &gt;10 mg/kg of chloroquine require medical attention [<a href="#rid105">105</a>]. Despite older reports suggesting otherwise, most experts consider the use of HCQ at usual therapeutic doses to be safe in patients with Class II and III glucose-6-phosphate dehydrogenase (G6PD) deficiency based on available data [<a href="#rid106">106</a>].</p><p class="headingAnchor" id="H18"><span class="h1">PREGNANCY AND LACTATION</span><span class="headingEndMark"> — </span>The safety of antimalarials when used during pregnancy and lactation in women with rheumatic disease is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation", section on 'Hydroxychloroquine'</a>.)</p><p class="headingAnchor" id="H746764647"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/120032.html" rel="external">"Society guideline links: Side effects of anti-inflammatory and anti-rheumatic drugs"</a>.)</p><p class="headingAnchor" id="H28"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/512.html" rel="external">"Patient education: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/513.html" rel="external">"Patient education: Rheumatoid arthritis treatment (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/583.html" rel="external">"Patient education: Disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H29"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>The immunoregulatory and antiinflammatory properties of the antimalarials <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a> (HCQ) and <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a> have been effective in the treatment of various systemic rheumatic disease and related conditions. (See <a class="local">'Noninfectious indications for antimalarials'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antimalarial drugs are administered orally, are relatively well-absorbed, and have a very long half-life; for <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a> and HCQ, it is one to two months. (See <a class="local">'Pharmacology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Excretion of the parent compound and hepatic metabolites is principally by direct renal clearance; dose reduction is appropriate for patients with impaired renal function. (See <a class="local">'Renal clearance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Many effects of antimalarial drugs have been documented. While it is unclear which is most important, blocking proinflammatory pathways is a common theme. (See <a class="local">'Mechanism of action'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who require HCQ for the treatment of systemic rheumatic diseases or related conditions, we suggest a daily dose of 5 mg/kg/day of actual body weight (maximum 400 mg/day) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Tablets may be split or variable dosing (eg, alternating or skipping doses on certain days) may be required to meet the recommended dose limits. Patients who weigh more than 80 kg can receive the standard daily dose of HCQ of 400 mg daily. Although comparable data for <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a> are lacking, dose comparisons have led to a suggested maximum daily dose of 2.3 mg/kg. (See <a class="local">'Dose adjustment for weight'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We advise assessment of ocular health within one year of starting long-term antimalarial drug therapy. The baseline examination should include a fundus examination of the macula to rule out any underlying disease that may interfere with the interpretation of screening tests. The frequency of screening during the first five years of treatment should be individualized based upon assessment of risk. At least annual screening should be performed for patients receiving treatment for more than five years. Patients should be alert for any change in visual acuity and should seek medical attention promptly if any visual loss is noted. (See <a class="local">'Routine eye examinations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antimalarials are among the safest medications used for the treatment of systemic rheumatic diseases. Serious side effects are rare. The most common adverse reactions are related to the gastrointestinal tract, skin, and central nervous system (CNS). The fear of vision-threatening toxic retinopathy remains the most serious concern. (See <a class="local">'Adverse effects'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Tett SE, Cutler DJ, Day RO. Bioavailability of hydroxychloroquine tablets assessed with deconvolution techniques. J Pharm Sci 1992; 81:155.</a></li><li><a class="nounderline abstract_t">Furst DE. Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. Lupus 1996; 5 Suppl 1:S11.</a></li><li><a class="nounderline abstract_t">Iredale J, Fieger H, Wainer IW. Determination of the stereoisomers of hydroxychloroquine and its major metabolites in plasma and urine following a single oral administration of racemic hydroxychloroquine. Semin Arthritis Rheum 1993; 23:74.</a></li><li><a class="nounderline abstract_t">Ducharme J, Fieger H, Ducharme MP, et al. Enantioselective disposition of hydroxychloroquine after a single oral dose of the racemate to healthy subjects. Br J Clin Pharmacol 1995; 40:127.</a></li><li><a class="nounderline abstract_t">Dencker L, Lindquist NG. Distribution of labeled chloroquine in the inner ear. Arch Otolaryngol 1975; 101:185.</a></li><li><a class="nounderline abstract_t">Easterbrook M. Is corneal deposition of antimalarial any indication of retinal toxicity? Can J Ophthalmol 1990; 25:249.</a></li><li><a class="nounderline abstract_t">Augustijns P, Geusens P, Verbeke N. Chloroquine levels in blood during chronic treatment of patients with rheumatoid arthritis. Eur J Clin Pharmacol 1992; 42:429.</a></li><li><a class="nounderline abstract_t">Furst DE, Lindsley H, Baethge B, et al. Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: a randomized, double-blind six-week trial with eighteen-week extension. Arthritis Rheum 1999; 42:357.</a></li><li><a class="nounderline abstract_t">Munster T, Gibbs JP, Shen D, et al. Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. Arthritis Rheum 2002; 46:1460.</a></li><li><a class="nounderline abstract_t">Cutler DJ, MacIntyre AC, Tett SE. Pharmacokinetics and cellular uptake of 4-aminoquinoline antimalarials. Agents Actions Suppl 1988; 24:142.</a></li><li class="breakAll">Rynes RI. Antimalarial Drugs. In: Textbook of Rheumatology, 5th Ed, Kelly WN, Harris ED Jr, Ruddy S, Sledge CB (Eds), WB Saunders, Philadelphia 1997.</li><li class="breakAll">Chloroquine phosphate USP prescribing information (October 2018) available at US National Library of Medicine DailyMed website https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=06c69e2b-211b-4746-9f3a-f86d36520570&amp;type=pdf&amp;name=06c69e2b-211b-4746-9f3a-f86d36520570 (Accessed on November 01, 2019).</li><li><a class="nounderline abstract_t">Mzayek F, Deng H, Mather FJ, et al. Randomized dose-ranging controlled trial of AQ-13, a candidate antimalarial, and chloroquine in healthy volunteers. PLoS Clin Trials 2007; 2:e6.</a></li><li><a class="nounderline abstract_t">Miller AK, Harrell E, Ye L, et al. Pharmacokinetic interactions and safety evaluations of coadministered tafenoquine and chloroquine in healthy subjects. Br J Clin Pharmacol 2013; 76:858.</a></li><li><a class="nounderline abstract_t">Valecha N, Savargaonkar D, Srivastava B, et al. Comparison of the safety and efficacy of fixed-dose combination of arterolane maleate and piperaquine phosphate with chloroquine in acute, uncomplicated Plasmodium vivax malaria: a phase III, multicentric, open-label study. Malar J 2016; 15:42.</a></li><li><a class="nounderline abstract_t">McGhie TK, Harvey P, Su J, et al. Electrocardiogram abnormalities related to anti-malarials in systemic lupus erythematosus. Clin Exp Rheumatol 2018; 36:545.</a></li><li><a class="nounderline abstract_t">Costedoat-Chalumeau N, Hulot JS, Amoura Z, et al. Heart conduction disorders related to antimalarials toxicity: an analysis of electrocardiograms in 85 patients treated with hydroxychloroquine for connective tissue diseases. Rheumatology (Oxford) 2007; 46:808.</a></li><li class="breakAll">Plaquenil hydroxychloroquine sulfate tablet USP prescribing information (January 2019) available at US National Library of Medicine DailyMed website https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=34496b43-05a2-45fb-a769-52b12e099341&amp;type=pdf&amp;name=34496b43-05a2-45fb-a769-52b12e099341 (Accessed on November 01, 2019).</li><li><a class="nounderline abstract_t">Nampoory MR, Nessim J, Gupta RK, Johny KV. Drug interaction of chloroquine with ciclosporin. Nephron 1992; 62:108.</a></li><li><a class="nounderline abstract_t">Finielz P, Gendoo Z, Chuet C, Guiserix J. Interaction between cyclosporin and chloroquine. Nephron 1993; 65:333.</a></li><li><a class="nounderline abstract_t">Leden I. Digoxin-hydroxychloroquine interaction? Acta Med Scand 1982; 211:411.</a></li><li><a class="nounderline abstract_t">Wallace DJ, Gudsoorkar VS, Weisman MH, Venuturupalli SR. New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. Nat Rev Rheumatol 2012; 8:522.</a></li><li><a class="nounderline abstract_t">Venuturupalli S, Gudsoorkar V, Wallace D. Reconsidering antimalarials in systemic lupus erythematosus: developments of translational clinical interest. J Rheumatol 2012; 39:1769.</a></li><li><a class="nounderline abstract_t">Leadbetter EA, Rifkin IR, Hohlbaum AM, et al. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002; 416:603.</a></li><li><a class="nounderline abstract_t">Means TK, Latz E, Hayashi F, et al. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest 2005; 115:407.</a></li><li><a class="nounderline abstract_t">Lafyatis R, York M, Marshak-Rothstein A. Antimalarial agents: closing the gate on Toll-like receptors? Arthritis Rheum 2006; 54:3068.</a></li><li><a class="nounderline abstract_t">Kyburz D, Brentano F, Gay S. Mode of action of hydroxychloroquine in RA-evidence of an inhibitory effect on toll-like receptor signaling. Nat Clin Pract Rheumatol 2006; 2:458.</a></li><li><a class="nounderline abstract_t">Kuznik A, Bencina M, Svajger U, et al. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol 2011; 186:4794.</a></li><li><a class="nounderline abstract_t">Petri M. Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus 1996; 5 Suppl 1:S16.</a></li><li><a class="nounderline abstract_t">Wallace DJ, Linker-Israeli M, Hyun S, et al. The effect of hydroxychloroquine therapy on serum levels of immunoregulatory molecules in patients with systemic lupus erythematosus. J Rheumatol 1994; 21:375.</a></li><li><a class="nounderline abstract_t">Jang CH, Choi JH, Byun MS, Jue DM. Chloroquine inhibits production of TNF-alpha, IL-1beta and IL-6 from lipopolysaccharide-stimulated human monocytes/macrophages by different modes. Rheumatology (Oxford) 2006; 45:703.</a></li><li><a class="nounderline abstract_t">Wozniacka A, Lesiak A, Narbutt J, et al. Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients. Lupus 2006; 15:268.</a></li><li><a class="nounderline abstract_t">Fox RI, Kang HI. Mechanism of action of antimalarial drugs: inhibition of antigen processing and presentation. Lupus 1993; 2 Suppl 1:S9.</a></li><li><a class="nounderline abstract_t">Fox R. Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development. Lupus 1996; 5 Suppl 1:S4.</a></li><li><a class="nounderline abstract_t">Weber SM, Levitz SM. Chloroquine interferes with lipopolysaccharide-induced TNF-alpha gene expression by a nonlysosomotropic mechanism. J Immunol 2000; 165:1534.</a></li><li class="breakAll">Wallace, DJ. Antimalarial therapies. In: Dubois' Lupus Erythematosus, 7th edition, Wallace, DJ, Hahn, BH (Eds), Williams &amp; Wilkins, Baltimore 2007.</li><li><a class="nounderline abstract_t">Stuhlmeier KM. Mepacrine inhibits matrix metalloproteinases-1 (MMP-1) and MMP-9 activation in human fibroblast-like synoviocytes. J Rheumatol 2003; 30:2330.</a></li><li><a class="nounderline abstract_t">Hu C, Lu L, Wan JP, Wen C. The Pharmacological Mechanisms and Therapeutic Activities of Hydroxychloroquine in Rheumatic and Related Diseases. Curr Med Chem 2017; 24:2241.</a></li><li><a class="nounderline abstract_t">SHAFFER B, CAHN MM, LEVY EJ. Absorption of antimalarial drugs in human skin; spectroscopic and chemical analysis in epidermis and corium. J Invest Dermatol 1958; 30:341.</a></li><li><a class="nounderline abstract_t">Wallace DJ. The use of quinacrine (Atabrine) in rheumatic diseases: a reexamination. Semin Arthritis Rheum 1989; 18:282.</a></li><li><a class="nounderline abstract_t">Wallace DJ. Is there a role for quinacrine (Atabrine) in the new millennium? Lupus 2000; 9:81.</a></li><li><a class="nounderline abstract_t">Marmor MF, Kellner U, Lai TY, et al. Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). Ophthalmology 2016; 123:1386.</a></li><li><a class="nounderline abstract_t">Rosenbaum JT, Costenbader KH, Desmarais J, et al. American College of Rheumatology, American Academy of Dermatology, Rheumatologic Dermatology Society, and American Academy of Ophthalmology 2020 Joint Statement on Hydroxychloroquine Use With Respect to Retinal Toxicity. Arthritis Rheumatol 2021; 73:908.</a></li><li><a class="nounderline abstract_t">Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol 2014; 132:1453.</a></li><li><a class="nounderline abstract_t">Wolfe F, Marmor MF. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2010; 62:775.</a></li><li><a class="nounderline abstract_t">Levy GD, Munz SJ, Paschal J, et al. Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice. Arthritis Rheum 1997; 40:1482.</a></li><li><a class="nounderline abstract_t">Mavrikakis I, Sfikakis PP, Mavrikakis E, et al. The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal. Ophthalmology 2003; 110:1321.</a></li><li><a class="nounderline abstract_t">Ding HJ, Denniston AK, Rao VK, Gordon C. Hydroxychloroquine-related retinal toxicity. Rheumatology (Oxford) 2016; 55:957.</a></li><li><a class="nounderline abstract_t">Marmor MF, Kellner U, Lai TY, et al. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology 2011; 118:415.</a></li><li><a class="nounderline abstract_t">Melles RB, Jorge AM, Marmor MF, et al. Hydroxychloroquine Dose and Risk for Incident Retinopathy : A Cohort Study. Ann Intern Med 2023; 176:166.</a></li><li><a class="nounderline abstract_t">Sontheimer RD. Questions answered and a $1 million question raised concerning lupus erythematosus tumidus: is routine laboratory surveillance testing during treatment with hydroxychloroquine for skin disease really necessary. Arch Dermatol 2000; 136:1044.</a></li><li><a class="nounderline abstract_t">Lee DH, Melles RB, Joe SG, et al. Pericentral hydroxychloroquine retinopathy in Korean patients. Ophthalmology 2015; 122:1252.</a></li><li><a class="nounderline abstract_t">Allahdina AM, Chen KG, Alvarez JA, et al. LONGITUDINAL CHANGES IN EYES WITH HYDROXYCHLOROQUINE RETINAL TOXICITY. Retina 2019; 39:473.</a></li><li><a class="nounderline abstract_t">Marmor MF, Hu J. Effect of disease stage on progression of hydroxychloroquine retinopathy. JAMA Ophthalmol 2014; 132:1105.</a></li><li><a class="nounderline abstract_t">Koneru S, Shishov M, Ware A, et al. Effectively measuring adherence to medications for systemic lupus erythematosus in a clinical setting. Arthritis Rheum 2007; 57:1000.</a></li><li><a class="nounderline abstract_t">Peterson AM, Takiya L, Finley R. Meta-analysis of trials of interventions to improve medication adherence. Am J Health Syst Pharm 2003; 60:657.</a></li><li><a class="nounderline abstract_t">Costedoat-Chalumeau N, Amoura Z, Hulot JS, et al. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum 2006; 54:3284.</a></li><li><a class="nounderline abstract_t">Costedoat-Chalumeau N, Amoura Z, Hulot JS, et al. Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus. Ann Rheum Dis 2007; 66:821.</a></li><li><a class="nounderline abstract_t">Durcan L, Clarke WA, Magder LS, Petri M. Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence. J Rheumatol 2015; 42:2092.</a></li><li><a class="nounderline abstract_t">Geraldino-Pardilla L, Perel-Winkler A, Miceli J, et al. Association between hydroxychloroquine levels and disease activity in a predominantly Hispanic systemic lupus erythematosus cohort. Lupus 2019; 28:862.</a></li><li><a class="nounderline abstract_t">Costedoat-Chalumeau N, Pouchot J, Guettrot-Imbert G, et al. Adherence to treatment in systemic lupus erythematosus patients. Best Pract Res Clin Rheumatol 2013; 27:329.</a></li><li><a class="nounderline abstract_t">Petri M, Elkhalifa M, Li J, et al. Hydroxychloroquine Blood Levels Predict Hydroxychloroquine Retinopathy. Arthritis Rheumatol 2020; 72:448.</a></li><li><a class="nounderline abstract_t">Garg S, Unnithan R, Hansen KE, et al. Clinical Significance of Monitoring Hydroxychloroquine Levels in Patients With Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis. Arthritis Care Res (Hoboken) 2021; 73:707.</a></li><li><a class="nounderline abstract_t">Tam LS, Gladman DD, Hallett DC, et al. Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus. J Rheumatol 2000; 27:2142.</a></li><li><a class="nounderline abstract_t">Wallace DJ, Metzger AL, Stecher VJ, et al. Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am J Med 1990; 89:322.</a></li><li><a class="nounderline abstract_t">Gerstein HC, Thorpe KE, Taylor DW, Haynes RB. The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas--a randomized trial. Diabetes Res Clin Pract 2002; 55:209.</a></li><li><a class="nounderline abstract_t">Wasko MC, Hubert HB, Lingala VB, et al. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA 2007; 298:187.</a></li><li><a class="nounderline abstract_t">Wallace DJ. Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus? Arthritis Rheum 1987; 30:1435.</a></li><li><a class="nounderline abstract_t">Rand JH, Wu XX, Quinn AS, et al. Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers. Blood 2008; 112:1687.</a></li><li><a class="nounderline abstract_t">Kaiser R, Cleveland CM, Criswell LA. Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort. Ann Rheum Dis 2009; 68:238.</a></li><li><a class="nounderline abstract_t">Rand JH, Wu XX, Quinn AS, et al. Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug. Blood 2010; 115:2292.</a></li><li><a class="nounderline abstract_t">Dawson LJ, Caulfield VL, Stanbury JB, et al. Hydroxychloroquine therapy in patients with primary Sjögren's syndrome may improve salivary gland hypofunction by inhibition of glandular cholinesterase. Rheumatology (Oxford) 2005; 44:449.</a></li><li><a class="nounderline abstract_t">Felson DT, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses. Arthritis Rheum 1990; 33:1449.</a></li><li><a class="nounderline abstract_t">Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010; 69:20.</a></li><li><a class="nounderline abstract_t">SCHERBEL AL, HARRISON JW, ATDJIAN M. Further observations on the use of 4-aminoquinoline compounds in patients with rheumatoid arthritis or related diseases. Cleve Clin Q 1958; 25:95.</a></li><li><a class="nounderline abstract_t">Giner Galvañ V, Oltra MR, Rueda D, et al. Severe acute hepatitis related to hydroxychloroquine in a woman with mixed connective tissue disease. Clin Rheumatol 2007; 26:971.</a></li><li><a class="nounderline abstract_t">Mates M, Zevin S, Breuer GS, et al. Desensitization to hydroxychloroquine--experience of 4 patients. J Rheumatol 2006; 33:814.</a></li><li><a class="nounderline abstract_t">Bahloul E, Jallouli M, Garbaa S, et al. Hydroxychloroquine-induced hyperpigmentation in systemic diseases: prevalence, clinical features and risk factors: a cross-sectional study of 41 cases. Lupus 2017; 26:1304.</a></li><li><a class="nounderline abstract_t">Jallouli M, Francès C, Piette JC, et al. Hydroxychloroquine-induced pigmentation in patients with systemic lupus erythematosus: a case-control study. JAMA Dermatol 2013; 149:935.</a></li><li><a class="nounderline abstract_t">Mosak J, Furie R. Comparative safety of therapies in systemic lupus erythematosus. Rheum Dis Clin North Am 2012; 38:795.</a></li><li><a class="nounderline abstract_t">Sorbara S, Cozzani E, Rebora A, Parodi A. Hydroxychloroquine in psoriasis: is it really harmful? Acta Derm Venereol 2006; 86:450.</a></li><li><a class="nounderline abstract_t">Weisholtz SJ, McBride PA, Murray HW, Shear MK. Quinacrine-induced psychiatric disturbances. South Med J 1982; 75:359.</a></li><li><a class="nounderline abstract_t">Hicklin JA. Chloroquine neuromyopathy. Ann Phys Med 1968; 9:189.</a></li><li><a class="nounderline abstract_t">Estes ML, Ewing-Wilson D, Chou SM, et al. Chloroquine neuromyotoxicity. Clinical and pathologic perspective. Am J Med 1987; 82:447.</a></li><li><a class="nounderline abstract_t">Casado E, Gratacós J, Tolosa C, et al. Antimalarial myopathy: an underdiagnosed complication? Prospective longitudinal study of 119 patients. Ann Rheum Dis 2006; 65:385.</a></li><li><a class="nounderline abstract_t">Morgan ND, Patel SV, Dvorkina O. Suspected hydroxychloroquine-associated QT-interval prolongation in a patient with systemic lupus erythematosus. J Clin Rheumatol 2013; 19:286.</a></li><li><a class="nounderline abstract_t">Vereckei A, Fazakas A, Baló T, et al. Chloroquine cardiotoxicity mimicking connective tissue disease heart involvement. Immunopharmacol Immunotoxicol 2013; 35:304.</a></li><li><a class="nounderline abstract_t">Stas P, Faes D, Noyens P. Conduction disorder and QT prolongation secondary to long-term treatment with chloroquine. Int J Cardiol 2008; 127:e80.</a></li><li><a class="nounderline abstract_t">Avina-Zubieta JA, Johnson ES, Suarez-Almazor ME, Russell AS. Incidence of myopathy in patients treated with antimalarials. A report of three cases and a review of the literature. Br J Rheumatol 1995; 34:166.</a></li><li><a class="nounderline abstract_t">Abdel-Hamid H, Oddis CV, Lacomis D. Severe hydroxychloroquine myopathy. Muscle Nerve 2008; 38:1206.</a></li><li><a class="nounderline abstract_t">Piette JC, Guillevin L, Chapelon C, et al. Chloroquine cardiotoxicity. N Engl J Med 1987; 317:710.</a></li><li><a class="nounderline abstract_t">Baguet JP, Tremel F, Fabre M. Chloroquine cardiomyopathy with conduction disorders. Heart 1999; 81:221.</a></li><li><a class="nounderline abstract_t">Pagell RL, O'Bryant CL, Cheng D, et al. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association. Circulation 2016; 134:e32.</a></li><li><a class="nounderline abstract_t">Silva JA, Silva MB, Skare TL. Chloroquine and QTc interval. Clin Exp Rheumatol 2007; 25:795.</a></li><li><a class="nounderline abstract_t">Bustos MD, Gay F, Diquet B, et al. The pharmacokinetics and electrocardiographic effects of chloroquine in healthy subjects. Trop Med Parasitol 1994; 45:83.</a></li><li><a class="nounderline abstract_t">Block JA. Hydroxychloroquine and retinal safety. Lancet 1998; 351:771.</a></li><li><a class="nounderline abstract_t">Rosenbaum JT, Mount GR, Youssef J, Lin P. New Perspectives in Rheumatology: Avoiding Antimalarial Toxicity. Arthritis Rheumatol 2016; 68:1805.</a></li><li><a class="nounderline abstract_t">Maturi RK, Yu M, Weleber RG. Multifocal electroretinographic evaluation of long-term hydroxychloroquine users. Arch Ophthalmol 2004; 122:973.</a></li><li><a class="nounderline abstract_t">Kellner U, Renner AB, Tillack H. Fundus autofluorescence and mfERG for early detection of retinal alterations in patients using chloroquine/hydroxychloroquine. Invest Ophthalmol Vis Sci 2006; 47:3531.</a></li><li><a class="nounderline abstract_t">Lai TY, Chan WM, Li H, et al. Multifocal electroretinographic changes in patients receiving hydroxychloroquine therapy. Am J Ophthalmol 2005; 140:794.</a></li><li><a class="nounderline abstract_t">Lyons JS, Severns ML. Using multifocal ERG ring ratios to detect and follow Plaquenil retinal toxicity: a review : Review of mfERG ring ratios in Plaquenil toxicity. Doc Ophthalmol 2009; 118:29.</a></li><li><a class="nounderline abstract_t">Shinjo SK, Maia OO Jr, Tizziani VA, et al. Chloroquine-induced bull's eye maculopathy in rheumatoid arthritis: related to disease duration? Clin Rheumatol 2007; 26:1248.</a></li><li><a class="nounderline abstract_t">Melles RB, Marmor MF. Pericentral retinopathy and racial differences in hydroxychloroquine toxicity. Ophthalmology 2015; 122:110.</a></li><li><a class="nounderline abstract_t">Rynes RI, Bernstein HN. Ophthalmologic safety profile of antimalarial drugs. Lupus 1993; 2 Suppl 1:S17.</a></li><li><a class="nounderline abstract_t">Smith ER, Klein-Schwartz W. Are 1-2 dangerous? Chloroquine and hydroxychloroquine exposure in toddlers. J Emerg Med 2005; 28:437.</a></li><li><a class="nounderline abstract_t">Mohammad S, Clowse MEB, Eudy AM, Criscione-Schreiber LG. Examination of Hydroxychloroquine Use and Hemolytic Anemia in G6PDH-Deficient Patients. Arthritis Care Res (Hoboken) 2018; 70:481.</a></li></ol></div><div id="topicVersionRevision">Topic 7964 Version 50.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1545355" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Bioavailability of hydroxychloroquine tablets assessed with deconvolution techniques.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8803904" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8278822" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Determination of the stereoisomers of hydroxychloroquine and its major metabolites in plasma and urine following a single oral administration of racemic hydroxychloroquine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8562294" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Enantioselective disposition of hydroxychloroquine after a single oral dose of the racemate to healthy subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1120003" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Distribution of labeled chloroquine in the inner ear.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2207871" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Is corneal deposition of antimalarial any indication of retinal toxicity?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1307690" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Chloroquine levels in blood during chronic treatment of patients with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10025931" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: a randomized, double-blind six-week trial with eighteen-week extension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12115175" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3263755" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Pharmacokinetics and cellular uptake of 4-aminoquinoline antimalarials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3263755" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Pharmacokinetics and cellular uptake of 4-aminoquinoline antimalarials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3263755" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Pharmacokinetics and cellular uptake of 4-aminoquinoline antimalarials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17213921" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Randomized dose-ranging controlled trial of AQ-13, a candidate antimalarial, and chloroquine in healthy volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23701202" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Pharmacokinetic interactions and safety evaluations of coadministered tafenoquine and chloroquine in healthy subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26818020" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Comparison of the safety and efficacy of fixed-dose combination of arterolane maleate and piperaquine phosphate with chloroquine in acute, uncomplicated Plasmodium vivax malaria: a phase III, multicentric, open-label study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29652656" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Electrocardiogram abnormalities related to anti-malarials in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17202178" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Heart conduction disorders related to antimalarials toxicity: an analysis of electrocardiograms in 85 patients treated with hydroxychloroquine for connective tissue diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17202178" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Heart conduction disorders related to antimalarials toxicity: an analysis of electrocardiograms in 85 patients treated with hydroxychloroquine for connective tissue diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1436274" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Drug interaction of chloroquine with ciclosporin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8247209" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Interaction between cyclosporin and chloroquine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7113754" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Digoxin-hydroxychloroquine interaction?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22801982" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : New insights into mechanisms of therapeutic effects of antimalarial agents in SLE.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22942300" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Reconsidering antimalarials in systemic lupus erythematosus: developments of translational clinical interest.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11948342" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15668740" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17009223" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Antimalarial agents: closing the gate on Toll-like receptors?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16951696" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Mode of action of hydroxychloroquine in RA-evidence of an inhibitory effect on toll-like receptor signaling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21398612" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8803905" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8182661" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The effect of hydroxychloroquine therapy on serum levels of immunoregulatory molecules in patients with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16418198" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Chloroquine inhibits production of TNF-alpha, IL-1beta and IL-6 from lipopolysaccharide-stimulated human monocytes/macrophages by different modes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16761500" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8097945" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Mechanism of action of antimalarial drugs: inhibition of antigen processing and presentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8803903" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10903761" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Chloroquine interferes with lipopolysaccharide-induced TNF-alpha gene expression by a nonlysosomotropic mechanism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10903761" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Chloroquine interferes with lipopolysaccharide-induced TNF-alpha gene expression by a nonlysosomotropic mechanism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14677173" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Mepacrine inhibits matrix metalloproteinases-1 (MMP-1) and MMP-9 activation in human fibroblast-like synoviocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28302011" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The Pharmacological Mechanisms and Therapeutic Activities of Hydroxychloroquine in Rheumatic and Related Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13563934" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Absorption of antimalarial drugs in human skin; spectroscopic and chemical analysis in epidermis and corium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2658071" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The use of quinacrine (Atabrine) in rheumatic diseases: a reexamination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10787002" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Is there a role for quinacrine (Atabrine) in the new millennium?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26992838" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33559327" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : American College of Rheumatology, American Academy of Dermatology, Rheumatologic Dermatology Society, and American Academy of Ophthalmology 2020 Joint Statement on Hydroxychloroquine Use With Respect to Retinal Toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25275721" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20535788" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9259429" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12867385" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26428520" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Hydroxychloroquine-related retinal toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21292109" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36645889" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Hydroxychloroquine Dose and Risk for Incident Retinopathy : A Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10926741" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Questions answered and a $1 million question raised concerning lupus erythematosus tumidus: is routine laboratory surveillance testing during treatment with hydroxychloroquine for skin disease really necessary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25712474" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Pericentral hydroxychloroquine retinopathy in Korean patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30741731" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : LONGITUDINAL CHANGES IN EYES WITH HYDROXYCHLOROQUINE RETINAL TOXICITY.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24922444" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Effect of disease stage on progression of hydroxychloroquine retinopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17665465" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Effectively measuring adherence to medications for systemic lupus erythematosus in a clinical setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12701547" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Meta-analysis of trials of interventions to improve medication adherence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17009263" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17324970" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26428205" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31122136" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Association between hydroxychloroquine levels and disease activity in a predominantly Hispanic systemic lupus erythematosus cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24238690" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Adherence to treatment in systemic lupus erythematosus patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31532077" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Hydroxychloroquine Blood Levels Predict Hydroxychloroquine Retinopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32004406" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Clinical Significance of Monitoring Hydroxychloroquine Levels in Patients With Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10990225" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2393036" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11850097" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas--a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17622600" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3435574" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18577708" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18782792" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19965621" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15590764" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Hydroxychloroquine therapy in patients with primary Sjögren's syndrome may improve salivary gland hypofunction by inhibition of glandular cholinesterase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1977391" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19103632" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13523829" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Further observations on the use of 4-aminoquinoline compounds in patients with rheumatoid arthritis or related diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16575495" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Severe acute hepatitis related to hydroxychloroquine in a woman with mixed connective tissue disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16463436" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Desensitization to hydroxychloroquine--experience of 4 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28355984" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Hydroxychloroquine-induced hyperpigmentation in systemic diseases: prevalence, clinical features and risk factors: a cross-sectional study of 41 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23824340" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Hydroxychloroquine-induced pigmentation in patients with systemic lupus erythematosus: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23137583" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Comparative safety of therapies in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16955195" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Hydroxychloroquine in psoriasis: is it really harmful?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7063914" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Quinacrine-induced psychiatric disturbances.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4298052" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Chloroquine neuromyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3826099" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Chloroquine neuromyotoxicity. Clinical and pathologic perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16096334" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Antimalarial myopathy: an underdiagnosed complication? Prospective longitudinal study of 119 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23872551" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Suspected hydroxychloroquine-associated QT-interval prolongation in a patient with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23409733" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Chloroquine cardiotoxicity mimicking connective tissue disease heart involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17590456" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Conduction disorder and QT prolongation secondary to long-term treatment with chloroquine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7704464" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Incidence of myopathy in patients treated with antimalarials. A report of three cases and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18720511" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Severe hydroxychloroquine myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3627179" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Chloroquine cardiotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9922366" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Chloroquine cardiomyopathy with conduction disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27400984" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18078640" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Chloroquine and QTc interval.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7939166" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : The pharmacokinetics and electrocardiographic effects of chloroquine in healthy subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9519945" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Hydroxychloroquine and retinal safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27111663" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : New Perspectives in Rheumatology: Avoiding Antimalarial Toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15249360" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Multifocal electroretinographic evaluation of long-term hydroxychloroquine users.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16877425" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Fundus autofluorescence and mfERG for early detection of retinal alterations in patients using chloroquine/hydroxychloroquine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16310457" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Multifocal electroretinographic changes in patients receiving hydroxychloroquine therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18465156" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Using multifocal ERG ring ratios to detect and follow Plaquenil retinal toxicity: a review : Review of mfERG ring ratios in Plaquenil toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17264974" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Chloroquine-induced bull's eye maculopathy in rheumatoid arthritis: related to disease duration?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25182842" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Pericentral retinopathy and racial differences in hydroxychloroquine toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8485566" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Ophthalmologic safety profile of antimalarial drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15837026" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Are 1-2 dangerous? Chloroquine and hydroxychloroquine exposure in toddlers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28556555" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Examination of Hydroxychloroquine Use and Hemolytic Anemia in G6PDH-Deficient Patients.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
